Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens

Abstract

An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The application claims the benefit of priority of U.S. Provisional Application No. 60 / 523,632 (attorney docket number 03495-6095), filed Nov. 21, 2003, which is incorporated herein by reference.FIELD OF THE INVENTION [0002] The invention relates to a recombinant adenylate cyclase toxin of Bordetella which induces T cell responses against tumoral antigens. BACKGROUND OF THE INVENTION [0003] This invention relates to compositions and methods for treating cancers. [0004] In many animal tumor models, T cells play an important role in tumor rejection. A variety of tumor antigens recognized by CD4+ or CD8+ tumor reactive T cells have been identified on both murine and human tumors (1). CD8+ cytotoxic lymphocytes (CTL) are of particular interest because these cells specifically recognize tumor cells and kill them. Therefore, an important goal in cancer immunotherapy is to activate tumor-specific CTL. [0005] Study of antigens recognized by CD8+...

AI Technical Summary

Benefits of technology

[0031]FIG. 1 depicts in vivo induction of CTL responses by recombinant CyaA carrying HLA*0201 restricted melanoma epitopes. HHD-mice received i.p. injections on days 0, 21 and 42 of either 50 μg control CyaA toxin (●, ◯) or recombinant CyaA toxins carrying melanoma epitopes (▪, □) (A, CyaA-Tyr; B, CyaA-GnT-V) in the presence of 1 mg alum. Seven days after the last injection, spleen cells from immune mice were stimulated in vitro with the priming peptide pTyr (A), or pGnT-V (B) in the presence of irradiated syngenic spleen cells. The cytotoxic activity of these effector cells was measured on 51Cr-labeled RMA-S-HHD target cells pulsed with the respective peptide (●, ▪) or incubated with medium alone (◯, □). The data represent mean values of duplicates (SD<10%). Quadrants represent the number of positive mice versus the number of tested mice, and curves represent mean values ± SD of responder mice per group from three experiments.

[0032]FIG. 2 depicts induction of melanoma-specific CTL responses by recombinant CyaA carrying melanoma epitopes using different routes of immunization. Panels A and B: HHD mice were immunized i.p. twice on days 0 and 21 with 50 μg

Problems solved by technology

The application of these approaches to human vaccination remains limited due to potential toxicity of adjuvants, bias towards the response against vector-derived epitopic peptide, or because they are “labor-demanding” (in vitro manipulated DC).

Images